ELSEVIED

Contents lists available at ScienceDirect

Transplant Immunology

journal homepage: www.elsevier.com/locate/trim



Development of mouse CD4⁺CD25⁺Foxp3⁺ regulatory T cells in xenogeneic pig thymic grafts

Baojun Zhang, Aijun Zhang, Yanyan Qu, Jun Liu, Zeqing Niu, Yong Zhao st

Transplantation Biology Research Division, State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China China–U.S. Research Center for Life Sciences, Chinese Academy of Sciences, Beijing, China

ARTICLE INFO

Article history: Received 3 July 2008 Received in revised form 1 September 2008 Accepted 10 September 2008

Keywords: Pig Thymus transplantation Regulatory T cells Foxp3 Tolerance

ABSTRACT

Xenogeneic thymus transplantation is an effective strategy to induce tolerance to donors mainly by clonal depletion of reactive T cells. Recent studies have shown that functional mouse CD4*CD25*Foxp3* regulatory T cells (Treg) could efficiently populate in the periphery of athymic mice after grafting with neonatal pig thymus. However, it is still unknown whether xenogeneic thymus grafts could directly support the development of mouse CD4*CD25*Foxp3* Treg cells as an autogeneic counterpart. Our results show that the percentages of mouse CD4*CD8*CD25* thymocytes are similar among auto- and xenogeneic thymic grafts in thymic mouse recipients. Mouse CD4*CD8*CD25* thymocytes maturing in xenogeneic thymic grafts exhibit similar expressions of Foxp3, TCR, CTLA-4 and GITR as those in autogeneic thymic grafts. Moreover, mouse CD4*CD8*CD25* thymocytes maturing in xenogeneic thymic grafts showed a significant immunosuppressive function on the proliferation of CD4*CD25* T cells stimulated with Con A or allogeneic antigens, although they showed weaker effects than those maturing in autogeneic thymic grafts. Therefore, the present data provides direct evidence for the ability of xenogeneic porcine thymus grafts to support the development of mouse naturally occurring CD4*CD25*Foxp3* Treg cells.

© 2008 Elsevier B.V. All rights reserved.

1. Introduction

Regulatory T cells (Treg), especially CD4⁺CD25⁺ Treg cells, play a key role in maintaining peripheral tolerance by active control of effector T cells, in addition to central tolerance induced by clonal deletion of T cells with high avidity for thymically expressed antigens. Depletion of functional CD4⁺CD25⁺ Treg cells leads to prominent autoimmune diseases such as diabetes, thyroiditis, bowel disease, and systemic lupus erythematosus [1–3]. This subpopulation of CD4⁺CD25⁺ Treg cells, which are mainly developed in the thymus, represents 5–10% of peripheral CD4⁺ T cells in healthy adult mice and humans [4–8]. CD4⁺ CD25⁺ Treg cells are characterized by several makers including Foxp3, CTLA-4, GITR and so on [9]. They are usually anergic but could potentially suppress the functions of CD4⁺CD25⁻ T or other immune cells [7,10]. Accumulating experimental and clinical evidence has

Abbreviations: CPM, counts per minute; CTLA-4, cytotoxic T lymphocyte-associated antigen 4; FCM, flow cytometry; FITC, fluorescein isothiocyanate; Foxp3, Forkhead box P3; GITR, Glucocorticoid-induced tumor-necrosis-factor-receptor family-related receptor; LNs, lymph nodes; mAbs, monoclonal antibodies; MLR, mix lymphocyte reaction; PBMCs, peripheral blood mononuclear cells; PE, phycoerythrin; PI, propidium iodide; TCR, T-cell receptor.

E-mail address: zhaoy@ioz.ac.cn (Y. Zhao).

demonstrated that CD4⁺CD25⁺ Treg cells are closely involved in transplant tolerance in humans and some mouse models [11–15].

Pigs are considered the best candidates for xenotransplantation because of their physiological and anatomical similarities to humans, and their efficient breeding and genetic manipulation [16-19]. Fetal or neonatal pig thymus (FP- or NP-THY) transplantation could reconstitute functional mouse CD4⁺ T cells in thymectomized. T celldepleted mice. These cells are specifically tolerant to donor pig antigens [20-22]. Recent studies demonstrated that a normal level of mouse CD4⁺CD25⁺ Treg cells was restored in the periphery of nude mice by grafting neonatal pig thymi [23]. These Treg cells shared similar characteristic expression of Foxp3, CTLA-4, GITR and CD62L with the counterparts of normal BALB/c mice. Also, they showed a similar T-cell receptor (TCR) V beta repertoire with normal BALB/c mice. More importantly, they exerted significant immunosuppression on the proliferation and interleukin-2 production of effector CD4⁺ CD25⁻ T cells induced by mitogen, alloantigens and peptide antigens in vitro [23]. The enhanced immunosuppression of CD4+CD25+ Treg cells isolated from NP-THY-graft nude mice on the response of effector T cells to donor antigens was determined in vitro [23], suggesting that xenogeneic thymus transplantation could induce tolerance to donor antigens not only by clonal depletion but also possibly by the contribution of CD4⁺CD25⁺ Treg cells [21]. However, it is still unclear whether peripheral mouse CD4+CD25+ Treg cells develop in xenogeneic porcine thymic grafts in a similar manner as in host thymus or whether they develop in the periphery of this mouse model.

^{*} Corresponding author. State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Datun Road, Beijing, 100101, China. Tel.: +86 10 64807302; fax: +86 10 64807302.

Therefore, we investigated the presence, characteristics and suppressive function of CD4*CD25*Foxp3* T cells in pig thymic grafts. Our results show that functional mouse CD4*CD25* Treg cells could develop in xenogeneic porcine thymic grafts as efficiently as autogeneic thymic grafts in nude mouse recipients. The present study offers direct evidence that xenogeneic pig thymus supports the development of mouse CD4*CD25* Treg cells.

2. Materials and methods

2.1. Animals and pig tissues

BALB/c mice (H-2^d, 8-week-old, female) and nude mice were purchased from the Beijing Laboratory Animal Research Center (Beijing, China). All mice were maintained in a specific pathogen-free facility and were housed in microisolator cages containing sterilized feed, autoclaved bedding, and water. Pregnant sows (70 days) or 2-day-old pigs were purchased from the China University




Fig. 1. Mouse thymocyte subpopulations in auto- and xenogeneic thymic grafts. By thymic transplantation for 10 weeks, thymocytes were stained with FITC-anti mCD4 mAb and PE-anti mCD8 mAb and analyzed by FCM. (A) One representative of thymocytes separated from auto- (, BALB/c thymic grafts, B-THY) and xenogeneic (neonatal or fetal pig thymic grafts, NP-THY or FP-THY) thymic grafts with anti-mCD4 and anti-mCD8 mAbs assayed by FCM (n=3-5). (B) The percentages of CD4SP, DP, DN and CD8 SP cells in different thymic grafts. (C) The total thymocyte number of thymic grafts. (D) The cell numbers of CD4 SP and CD8 SP thymocytes. Results were shown as mean ±SD, and 5 mice in each group were done. *, P<0.05; ****, P<0.001 compared among the indicated groups.




Fig. 2. The level of mouse CD4*CD8~CD25* thymocytes in auto- and xenogeneic thymic grafts. Cells from auto- and xenogeneic thymic grafts were stained with PE-CY5-anti-mCD4 mAb, FITC-anti-mCD8 mAb and PE-anti-mCD25 mAb and analyzed by FCM. (A) One representative of thymocytes of auto- and xenogeneic thymic grafts stained with three antibodies mentioned above and with gate on CD4*CD8¯ cells. (B) The average ratio of CD4*CD8⁻ tD25* to CD4*CD8¯ thymocytes in auto- and xenogeneic thymic grafts. (C) The cell numbers of CD4*CD8⁻ thymocytes in auto- and xenogeneic thymic grafts. Results were shown as mean±SD, and 5 mice in each group were done. No significant difference was detected among groups (*P*>0.05).

of Agriculture Sciences (Beijing, China). All experimental manipulations were undertaken in accordance with the Institutional Guidelines for the Care and Use of Laboratory Animals.




Fig. 3. Expression of mouse TCR on CD4*CD25* thymocytes. CD4 SP cells were purified from thymocytes of auto- and xenogeneic thymic grafts and stained with PE-CY5-anti-mCD4 mAb, FITC-anti-mCD25 mAb and PE-anti-mTCR mAb. (A) One representative of TCR staining in CD4*CD25*, CD4*CD25* and DP thymocytes. The broken and solid lines represent isotype control and specific mAb, respectively. (B) The percentages of TCR* cells in CD4*CD25*, CD4*CD25* and DP thymocytes of each group. (C) The mean of TCR on CD4*CD25*, CD4*CD25* and DP thymocytes of each group. Five mice in each group were performed. No significant difference was detected among groups (*P*>0.05).

2.2. Thymus transplantation

Mouse thymic tissues were isolated from 1-day-old BALB/c mice. Pig thymic tissues were isolated from fetal or 2-day-old neonatal pigs. Thymic tissues (~1 mm³) were kept in cold RPMI 1640 medium (Invitrogen, Beijing) and were then implanted under the kidney capsules of BALB/c nude mice under anesthesia with intraperitoneal injection of ketamine (0.08 mg/g; Bayer, Shawnee, Kansas).

2.3. Monoclonal antibodies (mAbs) and reagents

The following mAbs were purchased from either BD Biosciences PharMingen (San Diego, CA) or eBioscience (San Diego, CA). Fluorescein isothiocyanate (FITC)-labeled anti-mouse CD4 mAb (RM4-5; rat IgG2a), Phycoerythrin-CY5 (PE-CY5) labeled anti-mouse CD4mAb (H129.19; rat IgG2a), FITC-labeled anti-mouse CD8a mAb

(53-6.7; rat IgG2a), PE-labeled anti-mouse CD8a mAb (53-6.7; rat IgG2a), FITC-labeled anti-mouse CD25 mAb (7D4; rat IgM), PE-labeled anti-mouse CD25 mAb (PC61.5; rat IgG1), PE-labeled anti-mouse CD62L mAb (SK11; rIgG2a), PE-labeled anti-mouse glucocorticoid-induced tumor-necrosis-factor-receptor (GITR) mAb (DTA-1; rat IgG2b) and PE-labeled anti-mouse CD152 mAb (BNI3; mIgG2a). In addition, PE-labeled anti-mouse Foxp3 mAb (FJK-16s; rat IgG2a) and its staining kit were obtained from eBioscience (San Diego, CA). Rat anti-mouse FcR mAb (2.4G2; IgG2b) was produced by 2.4G2 hybridoma (ATCC, Rockville, Maryland) in our laboratory.

The culture medium used in the present study was RPMI 1640 (Hyclone, Logan, UT) supplemented with 10% heat-inactivated FCS, 100 U/ml penicillin, 100 μ g/ml streptomycin, 2 mM L-glutamine, 10 mM HEPES and 50 μ M 2-ME (Sigma, St. Louis, MO). Mitomycin C (C₁₅H₁₈N₄O₅) was obtained from Kyowa Hakko Co, Ltd. (Tokyo, Japan). [³H] thymidine was purchased from China Institute of Atomic Energy (Beijing, China).




Fig. 4. Expression of mouse Foxp3, CTLA-4 and GITR on CD4*CD25* thymocytes. CD4 SP cells were purified from thymocytes of auto- and xenogeneic thymic grafts, and were stained with PE-CY5-anti-mCD4 mAb, FITC-anti-mCD25 mAb and PE-anti-mFoxp3 mAb, PE-anti-mCTLA-4 mAb or PE-anti-mGITR mAb respectively. For detecting the expression of Foxp3 and CTLA-4, intracellular staining was performed. One representative and percentages of Foxp3 (A and B), CTLA-4 (C and D) or GITR (E and F) staining in CD4*CD25* thymocytes in each group. The broken and solid lines represent isotype control and specific mAb, respectively. Data was presented as mean ±SD (n=5). *P<0.05 compared with the control mice.

2.4. Immunofluorescence staining and flow cytometry (FCM)

Control thymus or thymic grafts were harvested and single cell suspensions were prepared by grinding the tissues with the plunger of a 5-ml disposable syringe and were then suspended in cold FCM buffer (PBS with 0.1% BSA and 0.1% NaN₃). Thymocytes were incubated with 2.4G2 to block FcRs and then incubated with an optimal concentration of mAbs for 30 min at 4 °C in the dark. Cells were washed three times, resuspended by FCM buffer and assayed using a FASCalibur flow cytometry (Becton Dickinson, CA). In some experiments, non-viable cells were excluded using the vital nucleic acid stain propidium iodide (PI). The data was analyzed with the CellQuest software.

For the intracellular staining, cells were incubated with PE-Cy5-labeled anti-CD4 and FITC-labeled anti-CD25 mAbs [24]. After washing, these cells were then stained with PE-labeled anti-mouse CD152 mAb or PE-labeled anti-mouse Foxp3 mAb, according to the instruction offered by the manufactory (eBiosciences, San Diego, CA).

2.5. Purification of mouse CD4⁺CD25⁺ and CD4⁺CD25⁻ thymocytes

Firstly, thymic CD8⁺ cells were deleted by anti-mCD8 mAb and complement. CD4⁺CD25⁻ T cells from CD8⁺ depleted thymocytes of normal BALB/c mice and CD4⁺CD25⁺ T cells from CD8⁺ cell-depleted thymocytes of thymus grafts were isolated using MicroBeads (Miltenyi Biotec, Auburn, CA) according to the manufacturer's instructions, respectively. The purity for CD4⁺CD8⁻CD25⁻ thymocytes was more than 95% and the purity for CD4⁺CD8⁻CD25⁺ thymocytes was more than 90% as determined by FCM in each experiment. Purified cells were suspended in complete RPMI 1640 medium.

2.6. The proliferation of T cells to Con A

BALB/c CD4*CD8^CD25^ thymocytes (1×10^5 cells/well) were cultured in U-bottom, 96-well plates with syngeneic accessory cells (1×10^5 splenocytes/well, pretreated with 30 µg/ml mitomycin C at 37 °C for 30 min), 2 µg/ml Con A and the indicated numbers of syngeneic CD4*CD8^ CD25* thymocytes isolated from either auto- or xenogeneic thymus grafts for 72 h at 37 °C, 5% CO2. 0.5 µCi [3 H] thymidine (185 GBq/mmol; Atomic Energy Research Establishment, China) was added to each well for the last 18 h [25]. Cells were harvested onto glass fiber filters with an automatic cell harvester (Tomtec, Toku, Finland). Samples were assayed in a Liquid Scintillation Analyzer (Beckmon Instruments, America). Values are presented as counts per minute (cpm) of triplicate wells.

2.7. Mixed lymphocyte reaction (MLR)

BALB/c CD4*CD8^CD25* thymoctyes were isolated from either control or TT mice as described above. BALB/c CD4*CD8^CD25^thymocytes were used as responder T cells. C57BL/6 splenocytes, which were pretreated with mitomycin C at the concentration of 30 µg/ml at 37 °C for 30 min, were used as allogeneic stimulator cells. Generally, 1×10^5 responder cells and 1×10^5 stimulator cells per well in RPMI1640 medium supplemented with 10% FCS were added in 96-well round-bottomed plates [26]. The indicated numbers of CD4*CD8^CD25* thymocytes were subsequently added to each well. Cells were cultured at 37 °C and 5% CO2 for 4 days. 0.5 μ Ci [3 H] thymidine was added for the last 18 h. Cells were harvested with an automatic cell harvester (Tomtec, Toku, Finland). The radioactivity of each sample was assayed in a Liquid Scintillation Analyzer (Beckmon Instruments, America). Values are expressed as counts per minute (cpm) of triplicate wells.

2.8. Statistical analysis

All data is presented as the mean \pm SD. Student's unpaired t test was used to compare groups. A P value of less than 0.05 was considered to be statistically significant.

3. Results

3.1. The presence of mouse CD4⁺CD8⁻CD25⁺ thymocytes in xenogeneic pig thymic grafts

The thymus is a vital central lymphoid organ where the majority of T cell subpopulations are generated through positive and negative selection. Naturally occurring CD4⁺CD25⁺ Treg cells expressing high affinity TCRs for self-peptide–MHC complexes could develop in the thymus by avoiding clonal deletion [27,28]. We initially observed the presence of mouse CD4⁺CD25⁺ Treg cells in pig thymic grafts by a FCM. BALB/c nude mice received autogeneic BALB/c thymus (B-THY), which were used as controls.

By 10 weeks after thymus transplantation, thymocytes from auto- and xenogeneic thymic grafts were stained by PE-anti-mCD8 mAb and FITC-anti-mCD4 mAb. As reported before [29], CD4 single positive (SP) cells showed similar population between these thymic grafts, whereas a significantly decreased percentage of single positive CD8 SP cells were observed in xenogeneic thymic grafts compared with autogeneic counterparts (Fig. 1A and B). Accordingly, the total cell number of thymocytes and CD4 SP cells among these groups shows no significant difference (Fig. 1C), but the cell number of CD8 SP cells shows a significant decrease in xenogeneic thymic grafts (Fig. 1D).

To determine the presence of $CD4^+CD25^+$ Treg cells in thymic grafts, we analyzed the thymic grafts by three-color staining with CY5-anti-mCD4, FITC-anti-mCD8 and PE-anti-mCD25 mAbs. The ratio of $CD4^+CD8^-CD25^+$ to $CD4^+CD8^-$ thymocytes and the cell number of $CD4^+CD8^-CD25^+$ thymocytes were similar among these thymic grafts (Fig. 2, P>0.05).

3.2. Phenotype of mouse CD4*CD8⁻CD25* thymocytes in auto- and xenogeneic thymic grafts

To characterize the phenotype of mouse CD4*CD8^CD25* thymocytes in xenogeneic thymic grafts, we compared the expression of CD4*CD25* Treg cell-specific makers, which are usually used to describe the phenotype of naturally occurring CD4*CD25* Treg cells including TCR, Foxp3, CTLA-4 and GITR, on CD4*CD25* and CD4*CD25* thymocytes in auto- and xenogeneic thymic grafts by a three-color FCM.

The conventional and mature CD4*T cells and CD4*CD25*Treg cells will become TCR^{high} in the thymus of mice before their transfer to periphery, Identical expression of TCR on either CD4*CD25* or CD4*CD25* cells was observed among auto- and xenogeneic thymic grafts (Fig. 3). Foxp3 was one of the key transcription factors in the development and function of




Fig. 5. Mouse CD4*CD8⁻CD25* T cells from auto- and xenogeneic thymic grafts showed significant immunosuppressive function on effector T cells. The proliferative assay was determined by [3 H]-TdR incorporation as described in Materials and methods. Thymic CD4*CD8⁻CD25⁻ T cells were stimulated with Con A (A) or MMC-treated allogeneic splenocytes (B) at the ratio of 1:1 in the presence of the indicated numbers of CD4*CD8⁻CD25* thymocytes separated from either auto- or xenogeneic thymic grafts. Cultures were incubated for 4 days and pulsed with [3 H] thymidine for the last 18 h. The data is presented as mean \pm SD of triplicate cultures. * 2 P<0.05, *** 4 P<0.001 compared among the indicated groups.

CD4*CD25* Treg cells [30]. Foxp3 was highly expressed among CD4*CD8-CD25* thymocytes in contrast to CD4*CD8-CD25* thymocytes (Fig. 4A and B). More importantly, Foxp3 was highly expressed in CD4*CD8-CD25* thymocytes in xenogeneic thymic grafts as similarly as autogeneic counterparts (Fig. 4A and B). In addition, the expression of CTLA-4 and GTR on CD4*CD8-CD25* and CD4*CD8-CD25* thymocytes in auto- and xenogeneic thymic grafts was detected. CD4*CD8-CD25* thymocytes express significantly less CTLA-4 and GTR compared to CD4*CD8-CD25* thymocytes. CD4*CD25* thymocytes in auto- or xenogeneic thymic grafts showed similar expression of CTLA-4 and GTR (Fig. 4C, D, E, and F).

3.3. Immunosuppressive function of mouse CD4⁺CD8⁻CD25⁺ thymocytes maturing in xenogeneic pig thymic grafts

After determining that mouse CD4*CD8^CD25* thymocytes developing in xenogeneic thymic grafts have similar phenotypic features of the counterpart in autogeneic thymic grafts, we studied the immunosuppressive ability of these CD4*CD8^CD25* thymocytes in an in vitro classic suppressive assay. CD4*CD8^CD25* thymocytes were purified from thymocytes of different thymic grafts. As shown in Fig. 5, CD4*CD8^CD25* thymocytes developing in different thymic grafts displayed significant inhibition on the proliferation of syngeneic mouse CD4*CD8^CD25^T cells to Con A (Fig. 5A) or allogeneic stimulators (Fig. 5B) in a dose-dependent manner, although mouse CD4*CD8^CD25^thymocytes maturing in xenogeneic pig thymic grafts showed reduced immunosuppressive function.

4. Discussion

Specific tolerance across a widely disparate species barrier can be achieved by grafting of fetal or neonatal pig thymic and liver tissue to T cell and NK cell-depleted, thymectomized mice [19,21]. It has been shown that mouse CD4*CD25* Treg cells could be reconstituted in the periphery of nude mice grafted with pig thymus [23]. In the present study, our results offer direct evidence supporting that mouse CD4*CD25* Treg cells can develop normally in xenogeneic thymic grafts in this model.

The majority of peripheral CD4⁺CD25⁺ Treg cells are naturally matured in the thymus. Foxp3 is a conservative transcription factor, which programs the development and suppressive function of CD4⁺ CD25⁺ Treg cells [31–33]. We observed that Foxp3 was highly expressed in mouse CD4⁺CD25⁺ thymocytes in xenogeneic thymic grafts in a similar level as those in autogeneic mouse thymic grafts. Furthermore, the expressions of CTLA-4 and CITR in mouse CD4⁺CD25⁺ thymocytes maturing in xenogeneic pig thymic grafts were identical to those in autogeneic thymic grafts or the reported results [34]. These data collectively suggest that xenogeneic pig thymic grafts have the ability to support the development of mouse CD4⁺CD25⁺Foxp3⁺ Treg cells.

In the porcine thymus-grafted athymic mouse model, it has been demonstrated that pig MHCs mediate the positive selection of mouse thymocytes and both mouse and pig MHCs are involved in the negative selection of mouse thymocytes in xenogeneic thymic grafts in mice [35–37]. CD4*CD25* Treg cell selection has been shown to require expression of self-antigen on radioresistant elements including cortical thymic epithelium (cTEC) and medullary thymic epithelium (mTEC) in the thymus [38]. It is speculated that expression of peptides in cTEC versus mTEC may be important in directing thymic CD4*CD25* Treg cell selection [39]. In xenogeneic pig thymic grafts, mouse CD4* T cell positive selection was mediated by donor pig MHCs. Whether donor pig MHCs mediate the positive selection of mouse CD4*CD25* Treg cells still needs to be determined.

The efficient immune regulatory function of thymic CD4⁺CD8⁻CD25⁺ cells has been demonstrated by significantly suppressing the proliferation of autologous CD4⁺CD25⁻ thymocytes to allogeneic stimulation by a contact-dependent mechanism in vitro [40–42]. In our study, mouse CD4⁺CD25⁺ thymocytes maturing in xenogeneic pig thymic grafts significantly inhibited the response of CD4⁺CD25⁻ T cells to Con A or allogeneic antigens in a dose-dependent fashion. However, mouse CD4⁺ CD25⁺ Treg cells obtained from xenogeneic pig thymic grafts showed a somewhat decreased immunosuppressive ability on effector T cells compared to autogeneic thymic counterparts. The reasons for the decreased immunosuppressive function of mouse CD4⁺CD25⁺ thymocytes are unclear so far, as it may be related to the xenogeneic donor MHCs-mediated positive selection in thymic grafts in these models.It was demonstrated that mouse CD8⁺ T cells always had poor recovery in

xenogeneic pig thymus-grafted nude mice. The poor recovery of mouse CD8⁺ T cells in the periphery of pig thymus-grafted athymic mice may be due to the poor migration ability of mouse CD8 single positive thymocytes from xenogeneic pig thymic grafts to the mouse periphery and/or the poor peripheral survival of mouse CD8⁺ T cells positively selected by pig MHCs in pig thymic grafts in these models [43].

In summary, efficient development of naturally occurring mouse CD4*CD25* Treg cells in xenogeneic pig thymic grafts was observed. The mouse CD4*CD25* Treg cells maturing in xenogeneic pig thymic grafts shared identical phenotypical characteristics with those maturing in autogeneic thymic grafts. More importantly, mouse CD4*CD25* Treg cells maturing in xenogeneic pig thymic grafts show significant immunosuppressive ability on the responses of syngeneic effector T cells. Nevertheless, our present data provides direct evidence supporting the development of mouse functional CD4*CD25* Treg cells in xenogeneic thymic grafts.

Acknowledgements

The authors wish to thank Dr. Narendra Jain for his review of the manuscript, Ms. Jing Wang, Ms. Jianxia Peng and Mr. Cunsheng Zhang for their expert technical assistance, and Ms. Qinghuan Li provided excellent laboratory management. This work was supported by grants from the National Natural Science Foundation for Distinguished Young Scholars (C03020504, Y.Z.), the Knowledge Innovation Program of Chinese Academy of Sciences (KSCX2-SW-333, Y.Z.), and the Scientific Research Foundation for the Returned Overseas Chinese Scholars of State Education Ministry (2005-546, Y.Z.).

References

- [1] Spence PJ, Green EA. Foxp3* regulatory T cells promiscuously accept thymic signals critical for their development. Proc Natl Acad Sci U S A 2008;105(3):973.
- [2] Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, et al. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol 2005;175(12):8392.
- [3] Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001;2(9):816.
- [4] Itoh M, Takahashi T, Sakaguchi N, Kuniyasu Y, Shimizu J, Otsuka F, et al. Thymus and autoimmunity: production of CD25⁺CD4⁺ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol 1999;162(9):5317.
- [5] Sakaguchi S, Sakaguchi N, Shimizu J, Yamazaki S, Sakihama T, Itoh M, et al. Immunologic tolerance maintained by CD25* CD4* regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001;182:18.
- [6] Shevach EM. CD4⁺ CD25⁺ suppressor T cells: more questions than answers. Nat Rev Immunol 2002;2(6):389.
- [7] Jonuleit H, Adema G, Schmitt E. Immune regulation by regulatory T cells: implications for transplantation. Transpl Immunol 2003;11(3–4):267.
- [8] Ng WF, Duggan PJ, Ponchel F, Matarese G, Lombardi G, Edwards AD, et al. Human CD4(+)CD25(+) cells: a naturally occurring population of regulatory T cells. Blood 2001;98(9):2736.
- [9] Sakaguchi S. Naturally arising Foxp3-expressing CD25*CD4* regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6(4):345.
- [10] Shevach EM, McHugh RS, Piccirillo CA, Thornton AM. Control of T-cell activation by CD4* CD25* suppressor T cells. Immunol Rev 2001;182:58.
- [11] Waldmann H, Graca L, Cobbold S, Adams E, Tone M, Tone Y. Regulatory T cells and organ transplantation. Semin Immunol 2004;16(2):119.
- [12] Jarvinen LZ, Blazar BR, Adeyi OA, Strom TB, Noelle RJ. CD154 on the surface of CD4*CD25* regulatory T cells contributes to skin transplant tolerance. Transplantation 2003;76(9):1375.
- [13] Meloni F, Vitulo P, Bianco AM, Paschetto E, Morosini M, Cascina A, et al. Regulatory CD4*CD25*T cells in the peripheral blood of lung transplant recipients: correlation with transplant outcome. Transplantation 2004;77(5):762.
- [14] Lee MKt, Moore DJ, Jarrett BP, Lian MM, Deng S, Huang X, et al. Promotion of allograft survival by CD4*CD25* regulatory T cells: evidence for in vivo inhibition of effector cell proliferation. J Immunol 2004;172(11):6539.
- [15] Hara M, Kingsley CI, Niimi M, Read S, Turvey SE, Bushell AR, et al. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo. J Immunol 2001;166(6):3789.
- 16] Sachs DH. The pig as a xenograft donor. Pathol Biol (Paris) 1994;42(3):217.
- [17] Sachs DH, Sykes M, Robson SC, Cooper DK. Xenotransplantation. Adv Immunol 2001;79:129.
- [18] Sykes M, Zhao Y, Yang YG. Tolerance induction for xenotransplantation. World J Surg 1997;21(9):932.

- [19] Khan A, Sergio JJ, Zhao Y, Pearson DA, Sachs DH, Sykes M. Discordant xenogeneic neonatal thymic transplantation can induce donor-specific tolerance. Transplantation 1997;63(1):124.
- [20] Lee LA, Gritsch HA, Sergio JJ, Arn JS, Glaser RM, Sablinski T, et al. Specific tolerance across a discordant xenogeneic transplantation barrier. Proc Natl Acad Sci U S A 1994:91(23):10864.
- [21] Zhao Y, Swenson K, Sergio JJ, Arn JS, Sachs DH, Sykes M. Skin graft tolerance across a discordant xenogeneic barrier. Nat Med 1996;2(11):1211.
- [22] Zhao Y, Fishman JA, Sergio JJ, Oliveros JL, Pearson DA, Szot GL, et al. Immune restoration by fetal pig thymus grafts in T cell-depleted, thymectomized mice. J Immunol 1997;158(4):1641.
- [23] Sun Z, Zhao L, Wang H, Sun L, Yi H, Zhao Y. Presence of functional mouse regulatory CD4'CD25* T cells in xenogeneic neonatal porcine thymus-grafted athymic mice. Am | Transplant 2006;6(12):2841.
- [24] Wang H, Zhao L, Sun Z, Sun L, Zhang B, Zhao Y. A potential side effect of cyclosporin A: inhibition of CD4(+)CD25(+) regulatory T cells in mice. Transplantation 2006:82(11):1484.
- [25] Qu Y, Zhang B, Zhao L, Liu G, Ma H, Rao E, et al. The effect of immunosuppressive drug rapamycin on regulatory CD4*CD25*Foxp3* T cells in mice. Transpl Immunol 2007:17(3):153.
- [26] Yi H, Zhen Y, Zeng C, Zhang L, Zhao Y. Depleting anti-CD4 monoclonal antibody (GK1.5) treatment: influence on regulatory CD4*CD25*Foxp3* T cells in mice. Transplantation 2008:85(8):1167
- [27] Neighbors M, Hartley SB, Xu X, Castro AG, Bouley DM, O'Garra A. Breakpoints in immunoregulation required for Th1 cells to induce diabetes. Eur J Immunol 2006;36(9):2315.
- [28] Qu Y, Zhao Y. Regulatory CD4(+)CD25(+) T-cells are controlled by multiple pathways at multiple levels. Int Rev Immunol 2007;26(3-4):145.
- [29] Zhao Y, Swenson K, Sergio JJ, Sykes M. Pig MHC mediates positive selection of mouse CD4* T cells with a mouse MHC-restricted TCR in pig thymus grafts. J Immunol 1998;161(3):1320.
- [30] Zhang L, Zhao Y. The regulation of Foxp3 expression in regulatory CD4(+)CD25(+)T cells: multiple pathways on the road. J Cell Physiol 2007;211(3):590.
- [31] Lio CW, Hsieh CS. A two-step process for thymic regulatory T cell development. Immunity 2008;28(1):100.

- [32] Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol 2006;24:209.
- [33] Campbell DJ, Ziegler SF. FOXP3 modifies the phenotypic and functional properties of regulatory T cells. Nat Rev Immunol 2007;7(4):305.
- 34] McHugh RS, Whitters MJ, Piccirillo CA, Young DA, Shevach EM, Collins M, et al. CD4(+) CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002;16(2):311.
- [35] Zhao Y, Sergio JJ, Swenson K, Arn JS, Sachs DH, Sykes M. Positive and negative selection of functional mouse CD4 cells by porcine MHC in pig thymus grafts. I Immunol 1997;159(5):2100.
- [36] Zhao Y, Rodriguez-Barbosa JI, Zhao G, Shaffer J, Arn JS, Sykes M. Maturation and function of mouse T-cells with a transgenic TCR positively selected by highly disparate xenogeneic porcine MHC. Cell Mol Biol (Noisy-le-grand) 2001;47(1):217.
- [37] Zhao Y, Rodriguez-Barbosa JI, Shimizu A, Sachs DH, Sykes M. Despite efficient intrathymic negative selection of host-reactive T cells, autoimmune disease may develop in porcine thymus-grafted athymic mice: evidence for failure of regulatory mechanisms suppressing autoimmunity. Transplantation 2003;75(11):1832.
- [38] Jordan MS, Boesteanu A, Reed AJ, Petrone AL, Holenbeck AE, Lerman MA, et al. Thymic selection of CD4*CD25* regulatory T cells induced by an agonist self-peptide. Nat Immunol 2001;2(4):301.
- [39] Bensinger SJ, Bandeira A, Jordan MS, Caton AJ, Laufer TM. Major histocompatibility complex class II-positive cortical epithelium mediates the selection of CD4(+)25(+) immunoregulatory T cells. J Exp Med 2001;194(4):427.
- [40] Maggi E, Cosmi L, Liotta F, Romagnani P, Romagnani S, Annunziato F. Thymic regulatory T cells. Autoimmun Rev 2005;4(8):579.
- [41] Liotta F, Cosmi L, Romagnani P, Maggi E, Romagnani S, Annunziato F. Functional features of human CD25* regulatory thymocytes. Microbes Infect 2005;7(7–8):1017.
- [42] Cosmi L, Liotta F, Lazzeri E, Francalanci M, Angeli R, Mazzinghi B, et al. Human CD8⁺ CD25⁺ thymocytes share phenotypic and functional features with CD4⁺CD25⁺ regulatory thymocytes. Blood 2003;102(12):4107.
- [43] Zhao Y, Barth RN, Swenson K, Pearson DA, Sykes M. Functionally and phenotypically mature mouse CD8⁺ T cells develop in porcine thymus grafts in mice. Xenotransplantation 1998;5:99.